Biohaven Ltd. (BHVN) Stock Forecast & Price Target

Compare

607 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BHVN Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Biohaven

Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BHVN Stock 12 Month Forecast

Average Price Target

$53.33

▲(217.63%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Biohaven Ltd. in the last 3 months. The average price target is $53.33 with a high forecast of $75.00 and a low forecast of $21.00. The average price target represents a 217.63% change from the last price of $16.79.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","34":"$34","48":"$48","62":"$62","76":"$76"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,34,48,62,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.45,26.49230769230769,30.534615384615385,34.57692307692308,38.61923076923077,42.661538461538456,46.70384615384616,50.746153846153845,54.78846153846153,58.830769230769235,62.87307692307692,66.91538461538461,70.95769230769231,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.45,24.825384615384614,27.20076923076923,29.576153846153844,31.951538461538462,34.32692307692307,36.70230769230769,39.0776923076923,41.45307692307692,43.82846153846154,46.20384615384615,48.57923076923076,50.95461538461538,{"y":53.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.45,22.338461538461537,22.226923076923075,22.115384615384613,22.003846153846155,21.892307692307693,21.78076923076923,21.66923076923077,21.557692307692307,21.446153846153845,21.334615384615383,21.223076923076924,21.111538461538462,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.18,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.1,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.31,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.57,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$75.00

Average Price Target$53.33

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$54

Buy

221.62%

Upside

Reiterated

05/30/25

Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

05/29/25

Optimistic Buy Rating for Biohaven Ltd. Amid Promising Pipeline and Regulatory Challenges

Marc GoodmanLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/29/25

Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements

Terence FlynnMorgan Stanley

Morgan Stanley

$63

Buy

275.22%

Upside

Reiterated

05/29/25

Morgan Stanley Keeps Their Buy Rating on Biohaven Ltd. (BHVN)

Tyler Van BurenTD Cowen

TD Cowen

$75

Buy

346.69%

Upside

Reiterated

05/29/25

Biohaven Ltd. (BHVN) Receives a Buy from TD Cowen

Jason GerberryBank of America Securities

Bank of America Securities

$54→$50

Buy

197.80%

Upside

Reiterated

05/28/25

Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating

Leonid TimashevRBC Capital

RBC Capital

$21

Hold

25.07%

Upside

Reiterated

05/28/25

RBC Capital Sticks to Their Hold Rating for Biohaven Ltd. (BHVN)

Tessa RomeroJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/14/25

Biohaven Ltd.'s Resilience and Strategic Growth Potential Amidst Regulatory Challenges

Brian SkorneyRobert W. Baird

Robert W. Baird

$60→$57

Buy

239.49%

Upside

Reiterated

04/28/25

Biohaven price target lowered to $57 from $60 at BairdBiohaven price target lowered to $57 from $60 at Baird

Allison BratzelPiper Sandler

Piper Sandler

$76

Buy

352.65%

Upside

Reiterated

03/07/25

Piper Sandler Keeps Their Buy Rating on Biohaven Ltd. (BHVN)

William PickeringBernstein

Bernstein

$73→$57

Buy

239.49%

Upside

Reiterated

03/05/25

Optimistic Buy Rating for Biohaven Ltd. Amid Regulatory Prospects and Long-term Growth Potential

Thomas ShraderBTIG

BTIG

$59

Buy

251.40%

Upside

Reiterated

02/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (NYSE: MDT), Biohaven Ltd. (NYSE: BHVN) and Arvinas Holding Company (NASDAQ: ARVN)

David HoangDeutsche Bank

Deutsche Bank

$65

Buy

287.14%

Upside

Initiated

02/11/25

Biohaven initiated with a Buy at Deutsche BankBiohaven initiated with a Buy at Deutsche Bank

Amy LiJefferies

Jefferies

$64

Buy

281.18%

Upside

Assigned

12/17/24

Promising Pipeline Developments and BHV-1300 Efficacy Boost Biohaven Ltd.'s Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$54

Buy

221.62%

Upside

Reiterated

05/30/25

Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

05/29/25

Optimistic Buy Rating for Biohaven Ltd. Amid Promising Pipeline and Regulatory Challenges

Marc GoodmanLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/29/25

Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements

Terence FlynnMorgan Stanley

Morgan Stanley

$63

Buy

275.22%

Upside

Reiterated

05/29/25

Morgan Stanley Keeps Their Buy Rating on Biohaven Ltd. (BHVN)

Tyler Van BurenTD Cowen

TD Cowen

$75

Buy

346.69%

Upside

Reiterated

05/29/25

Biohaven Ltd. (BHVN) Receives a Buy from TD Cowen

Jason GerberryBank of America Securities

Bank of America Securities

$54→$50

Buy

197.80%

Upside

Reiterated

05/28/25

Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating

Leonid TimashevRBC Capital

RBC Capital

$21

Hold

25.07%

Upside

Reiterated

05/28/25

RBC Capital Sticks to Their Hold Rating for Biohaven Ltd. (BHVN)

Tessa RomeroJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/14/25

Biohaven Ltd.'s Resilience and Strategic Growth Potential Amidst Regulatory Challenges

Brian SkorneyRobert W. Baird

Robert W. Baird

$60→$57

Buy

239.49%

Upside

Reiterated

04/28/25

Biohaven price target lowered to $57 from $60 at BairdBiohaven price target lowered to $57 from $60 at Baird

Allison BratzelPiper Sandler

Piper Sandler

$76

Buy

352.65%

Upside

Reiterated

03/07/25

Piper Sandler Keeps Their Buy Rating on Biohaven Ltd. (BHVN)

William PickeringBernstein

Bernstein

$73→$57

Buy

239.49%

Upside

Reiterated

03/05/25

Optimistic Buy Rating for Biohaven Ltd. Amid Regulatory Prospects and Long-term Growth Potential

Thomas ShraderBTIG

BTIG

$59

Buy

251.40%

Upside

Reiterated

02/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (NYSE: MDT), Biohaven Ltd. (NYSE: BHVN) and Arvinas Holding Company (NASDAQ: ARVN)

David HoangDeutsche Bank

Deutsche Bank

$65

Buy

287.14%

Upside

Initiated

02/11/25

Biohaven initiated with a Buy at Deutsche BankBiohaven initiated with a Buy at Deutsche Bank

Amy LiJefferies

Jefferies

$64

Buy

281.18%

Upside

Assigned

12/17/24

Promising Pipeline Developments and BHV-1300 Efficacy Boost Biohaven Ltd.'s Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biohaven Ltd.

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+4.87%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +4.87% per trade.

3 Months

xxx

Success Rate

9/19 ratings generated profit

Average Return

+8.81%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of +8.81% per trade.

1 Year

Thomas ShraderBTIG

Success Rate

9/19 ratings generated profit

Average Return

+29.39%

reiterated a buy rating 4 months ago

Copying Thomas Shrader's trades and holding each position for 1 Year would result in 47.37% of your transactions generating a profit, with an average return of +29.39% per trade.

2 Years

xxx

Success Rate

4/19 ratings generated profit

Average Return

-18.56%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 21.05% of your transactions generating a profit, with an average return of -18.56% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BHVN Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BHVN has received 30 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BHVN average Analyst price target in the past 3 months is 53.33.

Each month's total comprises the sum of three months' worth of ratings.

BHVN Financial Forecast

BHVN Earnings Forecast

Next quarter’s earnings estimate for BHVN is -$1.94 with a range of -$2.42 to -$1.49. The previous quarter’s EPS was -$2.17. BHVN beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year BHVN has Outperformed its overall industry.

No data currently available

BHVN Sales Forecast

Next quarter’s sales forecast for BHVN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year BHVN has Preformed in-line its overall industry.

BHVN Stock Forecast FAQ

What is BHVN’s average 12-month price target, according to analysts?

Based on analyst ratings, Biohaven Ltd.’s 12-month average price target is 53.33.

What is BHVN’s upside potential, based on the analysts’ average price target?

Biohaven Ltd. has 217.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BHVN a Buy, Sell or Hold?

Biohaven Ltd. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Biohaven Ltd.’s price target?

The average price target for Biohaven Ltd. is 53.33. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $21.00. The average price target represents 217.63% Increase from the current price of $16.79.

What do analysts say about Biohaven Ltd.?

Biohaven Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of BHVN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Biohaven Ltd. (BHVN) Stock Forecast & Price Target

BHVN Analyst Ratings

BHVN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biohaven Ltd.

BHVN Analyst Recommendation Trends

BHVN Financial Forecast

BHVN Earnings Forecast

BHVN Sales Forecast

BHVN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts